AI accelerates drug repurposing, but market incentives remain a bottleneck
import_jmr · x · 2026-08-18
An economics paper highlights a 'Missing Market for Innovation' where old drugs like aspirin sit unused for new purposes because companies lack profit incentives once patents expire. AI can find these matches faster, but the bottleneck is funding for trials. Nonprofit Every Cure uses AI to score drug-disease pairs and relies on philanthropy and public grants to validate them, uncoupling discovery from profit.
More from AGI Musings
- Quotes on the AI era: Complaining is prompting, walls are portals — debreuil · 2026-08-18
- Alex Wiltschko: AI Usage to Surpass Biological Intelligence in Digital Worlds First — graceisford · 2026-08-18
- Derya moves his reverse-aging prediction up to 2040, blaming early AGI — DeryaTR_ · 2026-08-18
- AI collapsed the cost of trying ideas, but our old filters remain — dfinke · 2026-08-18
- AI collapsed the cost of exploring ideas, but our instincts still price exploration high — dfinke · 2026-08-18
- After exhausting the open web, AI scrapers now hammer €7/month self-hosted servers — cen6wkf · 2026-08-18